TOKYO – Hoping to combine the affordability of biosimilars with the promise of combination cancer therapies, London-based Astrazeneca plc is making its first foray into biosimilar development through a joint venture with Fujifilm Kyowa Kirin Biologics Co. Ltd. (FKB).